NCT04419532 - A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 9, 2020

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

Solid TumorAdvanced CancerMetastatic Solid Tumor

Interventions

DRUG

DS-1055a

"Administered as an intravenous infusion on Day 1 of every 21-day cycle following low dose administration(s) in priming dose period.~Infusion duration: 180 minutes for the first infusion, and if no infusion-related reaction, 120 minutes for subsequent infusions"

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, New York

45219

University of Cincinnati Cancer Center, Cincinnati

M5G 2C1

Princess Margaret Cancer Center, Toronto

104-0045

National Cancer Center Hospital, Chūōku

277-8577

National Cancer Center Hospital East, Kashiwa

135-8550

Cancer Institute Hospital of JFCR, Kōtoku